T
Theriva Biologics, Inc. (TOVX)
ASE – Real Time Price. Currency in USD
0.25
+0.01 (4.52%)
At close: Jun 26, 2026, 4:00 PM EDT
0.24
-0.01 (-3.84%)
After-hours: Jun 26, 2026, 7:55 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.25
+0.01 (4.52%)
At close: Jun 26, 2026, 4:00 PM EDT
0.24
-0.01 (-3.84%)
After-hours: Jun 26, 2026, 7:55 PM EDT
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral β-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
| Name | Position |
|---|---|
| Dr. Ramon Alemany Ph.D. | Senior Vice President of Discovery |
| Dr. Vince Wacher Ph.D. | Senior Vice President of Corporate & Product Development |
| Mr. Steven A. Shallcross CPA | CEO, CFO, Treasurer, Corporate Secretary & Director |
| Date | Type | Document |
|---|---|---|
| 2026-06-18 | PRE 14A | tm2618124d1_pre14a.htm |
| 2026-06-11 | 8-K | tm2617564d1_8k.htm |
| 2026-06-05 | 8-K | tm2616886d1_8k.htm |
| 2026-05-05 | 8-K | tm2613605d1_8k.htm |
| 2026-05-05 | 10-Q | tmb-20260331x10q.htm |
| 2026-04-20 | PRE 14A | tm2612245d1_pre14a.htm |
| 2026-04-17 | 8-K | tm2612012d1_8k.htm |
| 2026-04-09 | 8-K | tm2611468d1_8k.htm |
| 2026-03-23 | 8-K | tm269559d1_8k.htm |
| 2026-03-16 | DEF 14A | tm267779-2_def14a.htm |